Mubritinib

Mubritinib
Clinical data
Routes of
administration		 Oral
ATC code none
Legal status
Legal status
  • Uncontrolled
Identifiers
CAS Number 366017-09-6
PubChem (CID) 6444692
IUPHAR/BPS 6011
ChemSpider 4948554
UNII V734AZP9BR YesY
ChEMBL CHEMBL1614707
Chemical and physical data
Formula C25H23F3N4O2
Molar mass 468.47 g/mol
3D model (Jmol) Interactive image

Mubritinib (TAK-165) is a protein kinase inhibitor which was under development by Takeda for the treatment of cancer.[1][2][3] It completed phase I clinical trials but appears to have been discontinued, as no new information on the drug has surfaced since December 2008.[4]

Synthesis

See also

References

  1. ↑ McCormick, Frank; Doriano Fabbro (2005). Protein Tyrosine Kinases: From Inhibitors to Useful Drugs (Cancer Drug Discovery and Development). Totowa, NJ: Humana Press. ISBN 1-58829-384-X.
  2. ↑ Mitscher, Lester A.; Lednicer, Daniel (1977). The organic chemistry of drug synthesis. New York: Wiley. ISBN 0-470-10750-2.
  3. ↑ Lednicer, Daniel (2008). Strategies for Organic Drug Synthesis and Design. New York: Wiley-Interscience. ISBN 0-470-19039-6.
  4. ↑ "Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 - Full Text View - ClinicalTrials.gov".


This article is issued from Wikipedia - version of the 10/23/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.